Endo International
 |
|
| Public | |
| Traded as |
NASDAQ: ENDP S&P 400 Component |
| Industry | Pharmaceutical |
| Headquarters | Dublin, Ireland and Malvern, Pennsylvania, U.S. |
| Website | www.endo.com |
Endo International plc is global specialty pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called "Endo Pharmaceuticals Inc."
Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQ: ENDP). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt.
On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company. Endo and Paladin Labs came together under Endo International plc and Endo established new global headquarters in Dublin, Ireland.
Endo develops, manufactures, markets and distributes branded and generic pharmaceutical products as well as over-the-counter medications though its operating companies - Endo Pharmaceuticals, Par Pharmaceutical, Paladin Labs, SOMAR and Litha. The company has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.
As of September 2016[update], Endo's chief executive officer (CEO) was Paul V. Campanelli. A prior CEO, Rajiv De Silva, had been appointed in February 2013.
As of September 2013[update], Endo's chief financial officer (CFO) was Suketu Upadhyay. A prior CFO, Charles A. Rowland Jr., had been appointed in December 2006.
Source:
Endo Pharmaceuticals once had the United States marketing rights for the FDA-approved Synera anesthetic patch for needle procedures. The agreement of 6 January 2006 for Endo Pharmaceuticals to market Synera (lidocaine plus tetracaine patch) was terminated on 31 July 2008. Endo is no longer involved with the Synera patch in the United States. Zars Pharmaceuticals was the patent holder for Synera. The rights to Synera passed to Nuvo Research of Canada in May 2011 upon the acquisition of ZARS Pharmaceuticals by Nuvo Research. Upon its purchase of Paladin Labs of Montreal, Endo once again became involved with the Synera patch by acquiring the rights to market Synera in Canada upon the approval of the Synera patch by Health Canada.
...
Wikipedia